title: Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer.
abstract: OBJECTIVE
  The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC).
  
  
  METHODS
  The treatment schedule included cisplatin at 40 mg/m(2) and vinorelbine at 25 mg/m(2) administered intravenously on days 1 and 8, every three weeks for four cycles.
  
  
  RESULTS
  This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77%) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76%) and anemia (12%). The average total doses of cisplatin and vinorelbine were 285 mg/m(2) and 177 mg/m(2), respectively.
  
  
  CONCLUSIONS
  The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.
authors: Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan. tseto@nk-cc.go.jp.
authors: Fumihiko
authors: F
authors: Hirai
authors: Takashi
authors: T
authors: Seto
authors: Mototsugu
authors: M
authors: Shimokawa
authors: Eiko
authors: E
authors: Inamasu
authors: Ryo
authors: R
authors: Toyozawa
authors: Gouji
authors: G
authors: Toyokawa
authors: Tsukihisa
authors: T
authors: Yoshida
authors: Yoshimasa
authors: Y
authors: Shiraishi
authors: Tomoyoshi
authors: T
authors: Takenaka
authors: Masafumi
authors: M
authors: Yamaguchi
authors: Mitsuhiro
authors: M
authors: Takenoyama
authors: Yukito
authors: Y
authors: Ichinose
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D014463:Ultrasonography; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine
keywords: Non-small cell lung cancer; adjuvant chemotherapy; cisplatin; split-dose; vinorelbine